Identification of novel follicular dendritic cell sarcoma markers, FDCSP and SRGN, by whole transcriptome sequencing

dc.contributor.author
Lorenzi, Luisa
dc.contributor.author
Döring, Claudia
dc.contributor.author
Rausch, Tobias
dc.contributor.author
Benes, Vladimir
dc.contributor.author
Lonardi, Silvia
dc.contributor.author
Bugatti, Mattia
dc.contributor.author
Campo Güerri, Elias
dc.contributor.author
Cabeçadas, José
dc.contributor.author
Simonitsch-Klupp, Ingrid
dc.contributor.author
Borges, Anita
dc.contributor.author
Mehta, Jay
dc.contributor.author
Agostinelli, Claudio
dc.contributor.author
Pileri, Stefano Aldo
dc.contributor.author
Facchetti, Fabio
dc.contributor.author
Hansmann, Martin-Leo
dc.contributor.author
Hartmann, Sylvia
dc.date.issued
2018-03-19T10:39:56Z
dc.date.issued
2018-03-19T10:39:56Z
dc.date.issued
2017-01-27
dc.date.issued
2018-03-19T10:39:56Z
dc.identifier
1949-2553
dc.identifier
https://hdl.handle.net/2445/120860
dc.identifier
671346
dc.identifier
28145886
dc.description.abstract
Follicular dendritic cell (FDC)-sarcoma is a rare neoplasm with morphologic and phenotypic features of FDCs. It shows an extremely heterogeneous morphology, therefore, its diagnosis relys on the phenotype of tumor cells. Aim of the present study was the identification of new specific markers for FDC-sarcoma by whole transcriptome sequencing (WTS). Candidate markers were selected based on gene expression level and biological function. Immunohistochemistry was performed on reactive tonsils, on 22 cases of FDC-sarcomas and 214 control cases including 114 carcinomas, 87 soft tissue tumors, 5 melanomas, 5 thymomas and 3 interdigitating dendritic cell sarcomas. FDC secreted protein (FDCSP) and Serglycin (SRGN) proved to be specific markers of FDC and related tumor. They showed better specificity and sensitivity values than some well known markers used in FDC sarcoma diagnosis (specificity: 98.6%, and 100%, respectively; sensitivity: 72.73% and 68.18%, respectively). In our cohorts CXCL13, CD21, CD35, FDCSP and SRGN were the best markers for FDC-sarcoma diagnosis and could discriminate 21/22 FDC sarcomas from other mesenchymal tumors by linear discriminant analysis. In summary, by WTS we identified two novel FDC markers and by the analysis of a wide cohort of cases and controls we propose an efficient marker panel for the diagnosis of this rare and enigmatic tumor.
dc.format
10 p.
dc.format
application/pdf
dc.format
application/pdf
dc.language
eng
dc.publisher
Impact Journals
dc.relation
Reproducció del document publicat a: https://doi.org/10.18632/oncotarget.14864
dc.relation
Oncotarget, 2017, vol. 8, num. 10, p. 16463-16472
dc.relation
https://doi.org/10.18632/oncotarget.14864
dc.rights
cc-by (c) Lorenzi, Luisa et al., 2017
dc.rights
http://creativecommons.org/licenses/by/3.0/es
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Fonaments Clínics)
dc.subject
Cèl·lules dendrítiques
dc.subject
Malalties rares
dc.subject
Tumors
dc.subject
Dendritic cells
dc.subject
Rare diseases
dc.subject
Tumors
dc.title
Identification of novel follicular dendritic cell sarcoma markers, FDCSP and SRGN, by whole transcriptome sequencing
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.